CLDI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Calidi Biotherapeutics Inc (CLDI) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is experiencing significant negative momentum, with a sharp decline in post-market trading (-35.04%) and a bearish technical setup. Additionally, the company's financial performance is weak, with no revenue growth, negative EPS, and a substantial net loss. The recent announcement of a public offering further pressures the stock price, and there are no positive catalysts or signals to suggest a recovery in the near term.
The technical indicators for CLDI are bearish. The MACD is slightly positive but contracting, indicating weakening momentum. The RSI is neutral at 43.044, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a significant post-market drop (-35.04%) suggesting further downside risk.
NULL identified.
Announcement of a public offering, which dilutes existing shareholders and pressures the stock price.
Significant post-market decline (-35.04%) following the news.
Weak financial performance with no revenue growth and a substantial net loss.
In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of -$10.82 million (up 114.13% YoY), and a negative EPS of -2.21 (down -71.48% YoY). Gross margin remains at 0%.
No analyst rating or price target changes available.
